SMALL CELL LUNG CANCER EXTENSIVE STAGE
Clinical trials for SMALL CELL LUNG CANCER EXTENSIVE STAGE explained in plain language.
Never miss a new study
Get alerted when new SMALL CELL LUNG CANCER EXTENSIVE STAGE trials appear
Sign up with your email to follow new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of drugs shows promise for tough lung cancer
Disease control OngoingThis phase II trial is testing whether adding two targeted drugs (pembrolizumab and lenvatinib) to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer growing. The study involves 46 participants who have not had prior…
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy aims to keep advanced lung cancer in check
Disease control OngoingThis early-phase trial tests whether adding chest radiation followed by immunotherapy drugs (durvalumab alone or with tremelimumab or olaparib) can help control extensive-stage small cell lung cancer after initial chemotherapy. About 25 adults whose cancer did not worsen after fi…
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take aim at tough lung cancer
Disease control OngoingThis early-phase study tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack DLL3, a protein found on certain lung cancer cells. The study includes about 41 adults with advanced small cell lung ca…
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a Chemo-Immunotherapy combo beat standard care for tough lung cancer?
Disease control OngoingThis phase 2 trial is testing whether a chemotherapy combination without etoposide (carboplatin plus paclitaxel) plus the immunotherapy drug durvalumab works better than standard treatment for people with extensive-stage small cell lung cancer. About 67 participants will receive …
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC